Head and neck cancer
Conditions
Interventions
Control group:Received conventional radiotherapy and placebo
Experimental group:Treated with conventional radiotherapy and thalidomide.
Sponsors
Zhejiang Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Gender is not limited; 2.Age 18-70 years old. 3.Pathologically confirmed head and neck carcinoma; 4.Performance Status 0-2; 5.Patients who received definitive or postoperative radiation therapy for head and neck region; 6.Enrolled patients must meet the following laboratory criteria: Hemoglobin (HGB) =100 g/L White blood cell count (WBC) >=4×10^9/L Platelet count (PLT) >=100×10^9/L (or WBC and platelet counts not below the lower limit of normal [LLN] per the institutional laboratory standards) Liver function: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <1.5× upper limit of normal (ULN) Total bilirubin <1.5×ULN Renal function: Serum creatinine <1.5×ULN; 7.Able to comprehend the study and signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1.History of other malignancies that may compromise the safety or efficacy of the current treatment; 2.Ppregnant or lactating women; 3.Patients currently participating in other investigational drug trials; 4.Documented history of deep vein thrombosis; 5.Previous history of radiotherapy to the head and neck region; 6.History of recurrent oral inflammation and autoimmune disorders including but not limited to systemic lupus erythematosus; 7.Any other conditions that may interfere with the study as determined by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of severe radiation-induced pharyngolaryngitis; | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of life;Incidence of adverse events (excluding radiation-induced pharyngolaryngitis); | — |
Countries
China
Contacts
Public ContactHua Yonghong
Zhejiang Cancer Hospital
Outcome results
None listed